Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Receivables (2021 - 2025)

Keros Therapeutics filings provide 4 years of Receivables readings, the most recent being $3.6 million for Q4 2025.

  • On a quarterly basis, Receivables rose 30.09% to $3.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.6 million, a 30.09% increase, with the full-year FY2025 number at $3.6 million, up 30.09% from a year prior.
  • Receivables hit $3.6 million in Q4 2025 for Keros Therapeutics, up from $3.5 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $18.0 million in Q4 2021 to a low of $4000.0 in Q2 2024.
  • Median Receivables over the past 4 years was $2.7 million (2024), compared with a mean of $5.6 million.
  • The widest YoY moves for Receivables: up 395300.0% in 2025, down 30.09% in 2025.
  • Keros Therapeutics' Receivables stood at $18.0 million in 2021, then plummeted by 99.21% to $143000.0 in 2023, then soared by 1817.48% to $2.7 million in 2024, then surged by 30.09% to $3.6 million in 2025.
  • The last three reported values for Receivables were $3.6 million (Q4 2025), $3.5 million (Q3 2025), and $15.8 million (Q2 2025) per Business Quant data.